Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: Analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies

Journal of Sexual Medicine

Volumn 10, Issue 8, 2013, Pages 2044-2052

  Porst, Hartmut ^a   Roehrborn, Claus G ^b   Secrest, Roberta J ^c   Esler, Anne ^d   Viktrup, Lars ^c  

^a Private Practice of Urology and Andrology   (Germany)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d PharmaNet i3   (United States)

Author keywords

Benign Prostatic Hyperplasia; Erectile Dysfunction; Lower Urinary Tract Symptoms; LUTS BPH; PDE5 Inhibitor; Tadalafil

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTATE SPECIFIC ANTIGEN; TADALAFIL; CARBOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; BACKACHE; BPH IMPACT INDEX; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; ERECTILE DYSFUNCTION; HUMAN; INTERNATIONAL INDEX OF ERECTILE FUNCTION; INTERNATIONAL INDEX OF ERECTILE FUNCTION ERECTILE FUNCTION; INTERNATIONAL PROSTATE SYMPTOM SCORE; IPSS SUBSCORE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MICTURITION; MULTICENTER STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE INDEX; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SEXUAL BEHAVIOR; TREATMENT DURATION; TREATMENT OUTCOME; URINE RETENTION; BLOOD; COMPLICATION; LOWER URINARY TRACT SYMPTOMS; MIDDLE AGED;

AGED; CARBOLINES; DOUBLE-BLIND METHOD; ERECTILE DYSFUNCTION; HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; MIDDLE AGED; PHOSPHODIESTERASE 5 INHIBITORS; PLACEBOS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; URINATION;

EID: 84881110118     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/jsm.12212     Document Type: Article

References (19)

1. McVary KT, McKenna KE. The relationship between erectile dysfunction and lower urinary tract symptoms: Epidemiological, clinical, and basic science evidence. Curr Urol Rep 2004;5:251-257.
2. Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, O'Leary MP, Puppo P, Robertson C, Giuliano F. Lower urinary tract symptoms and male sexual dysfunction: The multinational survey of the aging male (MSAM-7). Eur Urol 2003;44:637-649.
3. Seftel AD, de la Rosette J, Birt J, Porter V, Zarotsky V, Viktrup L. Coexisting lower urinary tract symptoms and erectile dysfunction: A systematic review of epidemiological data. Int J Clin Pract 2013;67:32-45.
4. Rosen RC, Link CL, O'Leary MP, Giuliano F, Aiyer LP, Mollon P. Lower urinary tract symptoms and sexual health: The role of gender, lifestyle and medical comorbidities. BJU Int 2009;103(suppl 3):42-47.
5. Rosen RC, Wei JT, Althof SE, Seftel AD, Miner M, Perelman MA. Association of sexual dysfunction with lower urinary tract symptoms of BPH and BPH medical therapies: Results from the BPH Registry. Urology 2009;73:562-566.
6. Gacci M, Eardley I, Giuliano F, Hatzichristou D, Kaplan SA, Maggi M, McVary KT, Mirone V, Porst H, Roehrborn CG. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2011;60:809-825.
7. Andersson KE, de Groat WC, McVary KT, Lue TF, Maggi M, Roehrborn CG, Wyndaele JJ, Melby T, Viktrup L. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Pathophysiology and mechanism(s) of action. Neurourol Urodyn 2011;30:292-301.
8. Giuliano F, Uckert S, Maggi M, Birder L, Kissel J, Viktrup L. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur Urol 2013;63:506-516.
9. Egerdie RB, Auerbach S, Roehrborn CG, Costa P, Garza MS, Esler AL, Wong DG, Secrest RJ. Tadalafil 2.5 or 5mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: Results of a randomized, placebo-controlled, double-blind study. J Sex Med 2012;9:271-281.
10. Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A dose finding study. J Urol 2008;180:1228-1234.
11. Porst H, Kim ED, Casabe AR, Mirone V, Secrest RJ, Xu L, Sundin DP, Viktrup L. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: Results of an international randomized, double-blind, placebo-controlled trial. Eur Urol 2011;60:1105-1113.
12. Oelke M, Giuliano F, Mirone V, Xu L, Cox D, Viktrup L. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol 2012;61:917-925.
13. Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992;148:1549-1557.
14. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822-830.
15. Broderick GA, Brock GB, Roehrborn CG, Watts SD, Elion-Mboussa A, Viktrup L. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction. Urology 2010;75:1452-1458.
16. Cialis [package insert]. Indianapolis, IN: Eli Lilly and Company. 2010.
17. Filippi S, Vignozzi L, Morelli A, Chavalmane AK, Sarchielli E, Fibbi B, Saad F, Sandner P, Ruggiano P, Vannelli GB, Mannucci E, Maggi M. Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome. J Sex Med 2009;6:3274-3288.
18. Zhang XH, Filippi S, Morelli A, Vignozzi L, Luconi M, Donati S, Forti G, Maggi M. Testosterone restores diabetes-induced erectile dysfunction and sildenafil responsiveness in two distinct animal models of chemical diabetes. J Sex Med 2006;3:253-264.
19. Morelli A, Comeglio P, Filippi S, Sarchielli E, Vignozzi L, Maneschi E, Cellai I, Gacci M, Lenzi A, Vannelli GB, Maggi M. Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome-associated prostate alterations: An experimental study in the rabbit. Prostate 2013;73:428-441.